Nature’s Sunshine Q1 expectations
This article was originally published in The Tan Sheet
Executive Summary
Net earnings for first quarter ended March 31 expected to be roughly 50% below analysts' estimates, Provo, Utah-based firm announces. Shortfall anticipated even before write-down of a long-term investment that became impaired near the end of the quarter. Although firm would not specify impairment, write-down will be about $3 mil. before tax, $2 mil. after tax. To offset losses, Nature's Sunshine has implemented a company-wide hiring freeze, instituted cost-cutting program. Q1 results expected to reflect 5% drop in U.S. sales, 11% decline in international revenue due to operating losses in Brazil, Japan. Full results are slated for release the week of April 22...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.